13F Pro quality score
Rank #2,755 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from IMPACT BIOMEDICAL INC.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $32.0K | $-11.8M | — |
| FY 2022 | 10-K | $50.0K | $-7.3M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
IMPACT BIOMEDICAL INC. (IBO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBO at 19.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,755 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), IMPACT BIOMEDICAL INC. reports quarterly revenue of $3.0K, net income of $-699.0K. Top institutional holders of IBO by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. IBO trades on the NYSE exchange and files with the SEC under CIK 1834105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMPACT BIOMEDICAL INC. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1834105 →